Cargando…
Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An in vitro and Preclinical Study
Visceral leishmaniasis (VL) has been a major health concern in the developing world, primarily affecting impoverished people. It is caused by a protozoan parasite Leishmania donovani and is characterized by immune dysfunction that can lead to deadly secondary infections. Several adverse side effects...
Autores principales: | Gedda, Mallikarjuna Rao, Madhukar, Prasoon, Vishwakarma, Alok Kumar, Verma, Vimal, Kushwaha, Anurag Kumar, Yadagiri, Ganesh, Mudavath, Shyam Lal, Singh, Om Prakash, Srivastava, Onkar Nath, Sundar, Shyam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350933/ https://www.ncbi.nlm.nih.gov/pubmed/32719770 http://dx.doi.org/10.3389/fchem.2020.00510 |
Ejemplares similares
-
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020) -
Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
por: Mudavath, Shyam Lal, et al.
Publicado: (2014) -
Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity
por: Parvez, Shabi, et al.
Publicado: (2020) -
Post kala-azar dermal leishmaniasis: A threat to elimination program
por: Gedda, Mallikarjuna Rao, et al.
Publicado: (2020) -
Strategies to Overcome Antileishmanial Drugs Unresponsiveness
por: Sundar, Shyam, et al.
Publicado: (2014)